相关实验视频
Updated: May 10, 2025

07:09
The Sciatic Nerve Cuffing Model of Neuropathic Pain in Mice
Published on: July 16, 2014
48.0K
评估患有慢性神经病痛和抑郁症的癌症患者的普雷加巴林:一个观察性病例系列
Pinaki Chakraborty1, Mrinal Borgohain2
1Department of Oncology, Gauhati Medical College and Hospital, Guwahati 781007, Assam, India.
World journal of clinical oncology
|April 28, 2025
概括
普雷加巴林有效地减少了癌症患者的疼痛和抑郁症. 这项研究强调了其作为一种可管理的副作用配置文件的治疗选择的潜力.
科学领域:
- 在瘤学瘤学.
- 疼痛管理 疼痛管理
- 精神病学是一个精神病学.
背景情况:
- 慢性神经病痛和抑郁症在癌症患者中很常见和令人衰弱.
- 这些情况显著损害了生活质量.
- 作为一种抗药,Pregabalin因其对疼痛和情绪的双重作用而受到研究.
研究的目的:
- 评估pregabalin在减少疼痛强度和抑郁症严重程度方面的有效性.
- 为了评估pregabalin在这个人群中的安全性和副作用概况.
主要方法:
- 10名患有神经病痛和抑郁症的癌症患者的观察案例系列.
- 普雷加巴林的剂量在每天两次从150毫克到300毫克不等.
- 疼痛 (简要疼痛库存) 和抑郁 (汉密尔顿抑郁评分表) 在基线,4周和8周被评估.
主要成果:
- 疼痛强度显著降低 (4周后33.3%,8周后47.4%) 和抑郁症严重程度 (4周后28.4%,8周后47.0%).
- 常见的副作用包括头,昏昏欲睡,体重增加和口腔干燥.
- 没有报告严重的不良事件;30%的患者需要调整剂量.
结论:
- 普雷加巴林在缓解癌症患者的慢性神经病痛和抑郁症方面表现出显著的有效性.
- 这种药物在这个患者群体中具有可管理的安全性.
- 建议对更大规模的受控研究进行进一步的研究,以证实这些发现.
相关概念视频
Analgesia and Pain Management
395
Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...
395
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
134
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
134
Antiepileptic Drugs: Potassium Channel Activators
119
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
119

